News

Public · Published

Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference

Helus Pharma Inc. (Cboe CA: HELP) said CEO Michael Halstead will take part in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston on November 9, 2026, at 3:00 p.m. EDT, with a live webcast and a replay on the company's investor relations website.

Published:

Updated:

What happened

Helus Pharma Inc. (Cboe CA: HELP) said CEO Michael Halstead will take part in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston on November 9, 2026, at 3:00 p.m. EDT, with a live webcast and a replay on the company's investor relations website.

Confirmed

Global impact / market context

A conference appearance gives a small clinical-stage drug developer a public stage to explain its depression treatment program to specialist healthcare investors. Such visibility can shape how well investors understand the company's progress and risks, which may influence their willingness to hold or buy the shares.

Analyst inference

Helus Pharma has no approved product and depends on costly clinical trials, so investor attention centers on trial progress rather than current sales. Events like this let management address questions on its Phase 3 program for HLP003, and the company also names Cybin, a reminder that mental health drug developers compete for the same specialist investor money.

Analyst inference

What to watch

  1. The fireside chat is scheduled for Monday, November 9, 2026, at 3:00 p.m. EDT, and a replay will be posted on the Events & Presentations page of Helus Pharma's investor relations website. Confirmed
  2. Listen for whether management gives a clearer timetable for HLP003's Phase 3 work in major depressive disorder, since trial timing affects how long the company must fund operations before any revenue. Proposed
  3. Watch whether the discussion highlights Helus Pharma's need to raise money for trials, because spending on clinical development without product sales can pressure cash available and dilute existing shareholders. Analyst inference

Evidence